How much improvement is needed for a real difference of lower urinary tract symptoms after long-term combination therapy for benign prostatic hyperplasia

2014 ◽  
Vol 68 (9) ◽  
pp. 1081-1086 ◽  
Author(s):  
Y.-H. Jiang ◽  
C.-H. Liao ◽  
H.-C. Kuo
Keyword(s):  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Combination Therapy ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Prostatic Hyperplasia ◽  
Real Difference ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms

2021 ◽  
Vol 14 (1) ◽  
pp. 58-62
Author(s):  
Tomasz Wiatr ◽  
Piotr Chłosta
Keyword(s):  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Overactive Bladder ◽  
Combination Therapy ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Prostatic Hyperplasia ◽  
Urinary Tract Symptoms ◽  
Frequency Score ◽  
Lower Urinary

Men with lower urinary tract symptoms (LUTS) treated with α-blockers may experience overactive bladder (OAB) symptoms and receive antimuscarinic drugs. Mirabegron (B3-adrenoreceptor agonist) is an alternative add-on therapy, that has been shown to be more effective than placebo in improving OAB symptoms. Superior results observed for tamsulosin plus mirabegron in mean volume voided per micturition, urgency episodes per day, and total urgency and frequency score. Higher rates of drug related treatment emergent adverse events were noted with tamsulosin plus mirabegron. The results of PLUS reveal the utility of mirabegron and tamsulosin therapy in the treatment of men with benign prostatic hyperplasia who developed symptoms of overactive bladder. The MATCH study confirmed that combination therapy for 12 weeks in men with symptoms of LUTS and OAB was more effective than placebo and was well tolerated.

Sign in / Sign up

Export Citation Format

Share Document